Report: Small deals aren't the answer to big pharma's woes

Drugmakers turned to less pricey — and less risky — M&A in 2017, but a new report outlines why such deals won't solve industry-wide issues.

By Jacob Bell • Jan. 18, 2018

Post-review, Aeterna Zentaris strikes commercialization deal

After a complicated year including a strategic review, Quebecois company Aeterna Zentaris inks a small deal to help it move forward. 

By Suzanne Elvidge • Jan. 18, 2018

Boehringer, hot on deals, adds another with Adimab collaboration

A new deal gives the German drugmaker access to antibodies against a range of targets.

By Suzanne Elvidge • Jan. 12, 2018

JPM18: No mega-deals for Lilly, Ricks says

A Lilly SVP for business development also updated BioPharma Dive on areas of focus. 

By Lisa LaMotta • Jan. 11, 2018

JPM18 Day 3: Valeant and Acorda make plans, promises of M&A

Attendees were a bit more pessimistic during the last full day of the J.P. Morgan Healthcare Conference, but a few biotech CEOs still brimmed with confidence.

By Ned Pagliarulo , Lisa LaMotta • Jan. 10, 2018

JPM18 Day 2: Roche on gene therapy, Aimmune nears key readout and outpatient CAR-T

No new billion-dollar deals were announced on the second day of the J.P. Morgan meeting. Yet investors appeared more optimistic, pushing biotech shares up.

By Ned Pagliarulo , Lisa LaMotta • Jan. 9, 2018

Teva, Alder ink migraine deal to avoid legal headache

Locked in a heated race to market, the companies agreed to exchange cash for a patent license so both could move forward.

By Jacob Bell • Jan. 9, 2018

JPM18: Alnylam and Sanofi reshuffle rare disease RNAi deal

The new agreement restores Alnylam's rights to its ATTR amyloidosis portfolio, as well as opens potential income streams.

By Suzanne Elvidge • Jan. 9, 2018

JPM18: Regeneron, Sanofi boost I/O investment

The closely knit pair upped their investment in their immuno-oncology candidate, extending a partnership.

By Lisa LaMotta • Jan. 8, 2018

Novo Nordisk puts $3B on the table for Ablynx

The Danish drugmaker's latest offer is 14% higher than its first, but Ablynx remains unimpressed.

By Jacob Bell • Jan. 8, 2018

Celgene aims to quell growth worries with $7B Impact deal

Buying Impact Biomedicines will give Celgene an NDA-ready blood disease drug to bolster a pipeline shaken by a recent setback.

By Ned Pagliarulo • Jan. 7, 2018

Taxes, tech and China to fuel pharma M&A in 2018, says EY

Repatriated cash coupled with growing competitive threats will leave the market 'ripe' for more life sciences deals, according to a new report.

By Jacob Bell • Jan. 7, 2018

With TiGenix buy and Denali deal, Takeda shows its hand

The Japan-based pharma has been eager to expand its global footprint, and two new agreements should help reinforce its presence in Europe and the U.S.

By Jacob Bell • Jan. 5, 2018

In surprise move, Pfizer hands back IDO1 inhibitor

iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.

By Suzanne Elvidge • Jan. 5, 2018

MacroGenics finds new pharma partner in Roche

After being stung by J&J's recent decision to drop a clinical candidate, Macrogenics has lined up another early-stage collaboration deal. 

By Ned Pagliarulo • Jan. 4, 2018

Pfizer targets harmful proteins in $830M deal

A research collaboration between the big pharma and Arvinas will focus on discovering therapies for disease-causing cellular proteins.

By Jacob Bell • Jan. 4, 2018

Indivior adds to addiction pipeline with Addex deal

The UK biotech takes on another addiction treatment after losing patent protection for its lead drug. 

By Lisa LaMotta • Jan. 3, 2018

Top 10 stories that had pharma execs talking

From CAR-T to potential deals, BioPharma readers dove into these pieces.

By Lisa LaMotta • Jan. 3, 2018

AstraZeneca sells US rights to 4 non-core drugs

Continuing its externalization drive, the British drugmaker stands to receive nearly $50 million for handing over several licenses and NDAs to ANI Pharmaceuticals.

By Jacob Bell • Jan. 2, 2018

Mallinckrodt builds pipeline through $1.2B Sucampo deal

Acquiring Sucampo gives the specialty drugmaker an on-market constipation drug and two Phase 3 candidates — just as sales of its top-seller run into headwinds.  

By Ned Pagliarulo • Dec. 26, 2017

Prescribed Reading: FDA approval spree, tax reform, deals pick up

The agency under Scott Gottlieb has hit a new record for approvals, and the new tax bill has already prompted M&A. 

By Lisa LaMotta • Dec. 22, 2017

Roche drops $1.7B for Ignyta and its lung cancer drug

Interim data from October found objective response rates as high as 78% in NSCLC patients with a type of gene rearrangement who took Ignyta's entrectinib.

By Jacob Bell • Dec. 22, 2017

J&J enters CAR-T field with $350M Legend deal

Legend Biotech burst onto the CAR-T scene at this year's ASCO meeting with impressive early results for its anti-BCMA cell therapy in multiple myeloma.   

By Ned Pagliarulo • Dec. 22, 2017

Biopharma trends to watch in 2018

Several macro trends will continue to shape the industry in the new year.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Dec. 22, 2017

MilliporeSigma tapped by bluebird for manufacturing

For bluebird, the deal is another step toward solidifying a stronger production process for its gene therapies.

By Jacob Bell • Dec. 21, 2017